Company Intelligence

Due diligence intelligence for active companies. Signal-scored across geopolitical exposure, regulatory risk, and sector tailwinds — ranked by composite risk/opportunity score.

Filters:🇺🇸 United States ✕

All energy technology financials healthcare industrials consumer materials utilities defense semiconductors mining pharma telecom shipping agriculture real_estate

All postures ✦ Opportunities ⚠ Risks

Themes for pharma

💊Pharma Supply Chain Reshoring

Total Tracked

Opportunities

Risk Flags

LLY +37

Top Score

✦

Opportunities

(6)

Ticker

Company

Sector

Action

Flag

Score

LLY

🇺🇸Eli Lilly and Company

Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) contin

Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) continues to take share from Novo Nordisk as s

Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) continues to take share from Novo Nordisk as supply normalizes and oral GLP-1 orforgli

pharma

EARLY

🇺🇸

RPRX

🇺🇸Royalty Pharma plc

Royalty Pharma is the largest buyer of biopharmaceutical roy

Royalty Pharma is the largest buyer of biopharmaceutical royalties, providing diversified non-operat

Royalty Pharma is the largest buyer of biopharmaceutical royalties, providing diversified non-operating exposure to top-selling drugs (Trele

pharma

EARLY

🇺🇸

+22—

AMGN

🇺🇸Amgen Inc.

Amgen's MariTide injectable GLP-1 with monthly dosing offers

Amgen's MariTide injectable GLP-1 with monthly dosing offers a credible third entrant to challenge L

Amgen's MariTide injectable GLP-1 with monthly dosing offers a credible third entrant to challenge Lilly/Novo if Phase 3 data reads out clea

pharma

EARLY

🇺🇸

+22—

GILD

🇺🇸Gilead Sciences Inc.

Gilead's lenacapavir long-acting HIV PrEP is a category-rede

Gilead's lenacapavir long-acting HIV PrEP is a category-redefining product approved for twice-yearly

Gilead's lenacapavir long-acting HIV PrEP is a category-redefining product approved for twice-yearly dosing, with strong real-world uptake.

pharma

EARLY

🇺🇸

+22—

ABBV

🇺🇸AbbVie Inc.

AbbVie is past the worst of Humira biosimilar erosion with S

AbbVie is past the worst of Humira biosimilar erosion with Skyrizi and Rinvoq combined trajectory ab

AbbVie is past the worst of Humira biosimilar erosion with Skyrizi and Rinvoq combined trajectory above $24B by 2027. Cerevel and ImmunoGen

pharma

EARLY

🇺🇸

+22—

VRTX

🇺🇸Vertex Pharmaceuticals Incorporated

Vertex's vanzacaftor triple CF combination launched smoothly

Vertex's vanzacaftor triple CF combination launched smoothly and improves both efficacy and royalty

Vertex's vanzacaftor triple CF combination launched smoothly and improves both efficacy and royalty economics. Suzetrigine non-opioid pain f

pharma

EARLY

🇺🇸

+22—

⚠

Risks

(3)

Ticker

Company

Sector

Action

Flag

Score

REGN

🇺🇸Regeneron Pharmaceuticals Inc.

Regeneron's Eylea HD launch is being squeezed by Roche's Vab

Regeneron's Eylea HD launch is being squeezed by Roche's Vabysmo and incoming aflibercept biosimilar

Regeneron's Eylea HD launch is being squeezed by Roche's Vabysmo and incoming aflibercept biosimilars. Patent litigation against Amgen and S

pharma

AVOID

🇺🇸

-34—

BMY

🇺🇸Bristol-Myers Squibb Company

BMY faces a compounding patent cliff with Revlimid already e

BMY faces a compounding patent cliff with Revlimid already eroded, Eliquis Medicare negotiation hitt

BMY faces a compounding patent cliff with Revlimid already eroded, Eliquis Medicare negotiation hitting 2026, and Opdivo LOE approaching. Th

pharma

AVOID

🇺🇸

-22—

MRK

🇺🇸Merck & Co. Inc.

Merck's Keytruda patent cliff in 2028 looms larger as oncolo

Merck's Keytruda patent cliff in 2028 looms larger as oncology pipeline replacements underwhelm in t

Merck's Keytruda patent cliff in 2028 looms larger as oncology pipeline replacements underwhelm in trials. The subcutaneous Keytruda formula

pharma

AVOID

🇺🇸

-22—